Artificial intelligence-driven comparative efficacy of topical crisaborole versus halometasone for vitiligo: A randomized and noninferiority study - 05/12/25
Doi : 10.1016/j.jaad.2025.11.032
Meng Wang, MBBS a, b, Jiayi Sun, MBBS a, b, Tianyu Wang, MBBS a, b, Zhenhua Yue, MD a, b, Guoyan Liu, MD a, b, Xiaoxiao Yan, MD a, b, Yonghu Sun, MD, PhD a, b, ⁎ 
, Furen Zhang, MD, PhD a, b
, Furen Zhang, MD, PhD a, b a Dermatology Hospital of Shandong First Medical University, Jinan, China
b Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, China
∗Correspondence to: Yonghu Sun, MD, PhD, Shandong Provincial Institute of Dermatology and Venereology, 27397 Jingshi Rd, Jinan, Shandong, ChinaShandong Provincial Institute of Dermatology and Venereology27397 Jingshi RdJinanShandongChina
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Friday 05 December 2025
Key words : crisaborole, halometasone, vitiligo
| Funding sources: This work was supported by the Taishan Scholars Program of Shandong Province (tsqn201909141), Shandong Provincial Key R & D Program (2025CXPTWZ002), the National Natural Science Foundation of China (82073441), and the Academic Promotion Programme of Shandong First Medical University ( 2020RC001 ). |
|
| Patient consent: Consent for the publication of recognizable patient photographs or other identifiable material was obtained by the authors and included at the time of article submission to the journal, stating that all patients gave consent with the understanding that this information may be publicly available. |
|
| IRB approval status: Reviewed and approved by the Shandong Provincial Hospital for Skin Diseases IRB. Approval: #SPHSD-2023-0412. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?